BL
BLCO.US Bausch + Lomb Corp
- Market cap
- USD 7.55B
- P/E
- -
- P/B
- 1.17x
- ROE
- -1.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BLCO.US undervalued?
Graham numberThe Graham number of Bausch + Lomb Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bausch + Lomb Corp fundamental analysis
No fundamental analysis for Bausch + Lomb Corp yet.
Bausch + Lomb Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bausch + Lomb Corp
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are in…
Full company profileBausch + Lomb Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bausch + Lomb Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 3.67B | 3.78B | 3.41B | 3.77B | 3.77B | 4.15B | 4.79B | 5.10B | 5.34B |
| Gross Profit | 2.35B | 2.45B | 2.13B | 2.30B | 2.25B | 2.50B | 2.92B | 2.79B | 3.14B |
| Operating Income | 416M | 396M | 260M | 329M | 207M | 130M | 162M | 188M | 396M |
| EBITDA | 922M | 936M | 732M | 733M | 598M | 499M | 601M | 535M | 632M |
| Net Income | 710M | 298M | -18.0M | 182M | 6.00M | -260M | -317M | -360M | -70.7M |
| EPS | 2.03 | 0.85 | -0.05 | 0.52 | 0.02 | -0.74 | -0.90 | -1.02 | -0.20 |
| Balance Sheet | |||||||||
| Total Assets | - | 11.5B | 11.3B | 10.8B | 11.1B | 13.4B | 13.5B | 14.0B | 14.0B |
| Total Liabilities | - | 1.44B | 1.28B | 1.42B | 4.04B | 6.52B | 6.93B | 7.50B | 7.45B |
| Shareholders' Equity | - | 9.96B | 9.92B | 9.33B | 7.03B | 6.85B | 6.47B | 6.45B | 6.44B |
| Cash & Short-term Investments | - | 192M | 238M | 174M | 380M | 334M | 305M | 383M | 513M |
| Total Debt | - | 93.0M | 101M | 140M | 2.55B | 4.68B | 4.94B | 5.37B | 5.10B |
| Cash Flow | |||||||||
| Operating Cash Flow | 763M | 799M | 522M | 873M | 345M | -17.0M | 232M | 283M | 557M |
| Capital Expenditure | 101M | 180M | 259M | 193M | 175M | 181M | 291M | 349M | 301M |
| Free Cash Flow | 662M | 619M | 263M | 680M | 170M | -198M | -59.0M | -66.0M | 256M |
| Ratios | |||||||||
| ROE | - | 3.0% | -0.2% | 2.0% | 0.1% | -3.8% | -4.9% | -5.6% | -1.1% |
| ROA | - | 2.6% | -0.2% | 1.7% | 0.1% | -1.9% | -2.4% | -2.6% | -0.5% |
| Net Profit Margin | 19.4% | 7.9% | -0.5% | 4.8% | 0.2% | -6.3% | -6.6% | -7.1% | -1.3% |
| Debt to Equity | - | 0.01x | 0.01x | 0.02x | 0.36x | 0.68x | 0.76x | 0.83x | 0.79x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bausch + Lomb Corp dividends
Bausch + Lomb Corp has not paid dividends in the last 8 fiscal years.
Who owns Bausch + Lomb Corp
- Insiders 87.12%
- Institutions 11.27%
- Public & others 1.61%
- Shares outstanding 357M
- Free float 46.4M
Top funds holding BLCO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| T. Rowe Price High Yield | 837K | 0.23% | 0.00% | Sep 2026 |
| Bestinver Norteamérica FI | 248K | 0.07% | -3.03% | Jun 2026 |
| T. Rowe Price Instl High Yield | 218K | 0.06% | 0.00% | Sep 2026 |
| Bestinver Grandes Compañías FI | 217K | 0.06% | 0.00% | Jun 2026 |
| T. Rowe Price Dynamic Credit I | 204K | 0.06% | 0.00% | Sep 2026 |
| Gabelli Health & Wellness | 144K | 0.04% | 0.00% | Jun 2026 |
| Ballast Small/Mid Cap ETF | 141K | 0.04% | 0.00% | Oct 2026 |
| Bestinver Megatendencias FI | 80.4K | 0.02% | 0.00% | Jun 2026 |
| Fidelity Tactical High Income Sr F8 | 75.5K | 0.02% | -92.19% | Mar 2026 |
| Gabelli Dividend & Income | 75.0K | 0.02% | -24.01% | Jun 2026 |
| T. Rowe Price Glb High Inc Bd I | 66.8K | 0.02% | 0.00% | Sep 2026 |
| T. Rowe Price Global High Income Bd | 62.0K | 0.02% | 0.00% | Sep 2026 |
| Bestinver Patrimonio FI | 57.0K | 0.02% | +40.57% | Jun 2026 |
| T. Rowe Price Credit Opportunities | 52.9K | 0.01% | 0.00% | Sep 2026 |
| T. Rowe Price Hi Yld Bd A Acc USD | 48.1K | 0.01% | 0.00% | Sep 2026 |
| Gabelli Asset AAA | 45.0K | 0.01% | 0.00% | Jun 2026 |
| Strategic Advisers Income Opportunities | 43.5K | 0.01% | -3.55% | Aug 2026 |
| iShares Ageing Population ETF USD Acc | 30.6K | 0.01% | 0.00% | Oct 2026 |
| Handelsbanken Global Småb Index (A1 NOK) | 22.0K | 0.01% | 0.00% | Oct 2026 |
| DFA International Core Equity 2 I | 17.0K | 0.00% | 0.00% | Sep 2026 |
Top institutions holding BLCO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| ICAHN CARL C | 3.50M | 0.98% | 0.00% | Jun 2026 |
| Oaktree Capital Management LLC | 3.44M | 0.96% | +1.72% | Jun 2026 |
| Deutsche Bank AG | 3.42M | 0.96% | -2.99% | Jun 2026 |
| D. E. Shaw & Co LP | 3.32M | 0.93% | +5.45% | Jun 2026 |
| Davidson Kempner Capital Management LP | 3.16M | 0.88% | +43.64% | Jun 2026 |
| Goldentree Asset Management LP | 2.66M | 0.74% | 0.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 2.16M | 0.60% | +76.48% | Jun 2026 |
| Caspian Capital Partners, L.P. | 2.00M | 0.56% | 0.00% | Jun 2026 |
| Glenview Capital Management LLC | 1.92M | 0.54% | +0.40% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 1.36M | 0.38% | +38.99% | Jun 2026 |
| Citadel Advisors Llc | 988K | 0.28% | +40.06% | Jun 2026 |
| Clark Estates Inc | 881K | 0.25% | +6.79% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 703K | 0.20% | -16.85% | Jun 2026 |
| Clearline Capital LP | 702K | 0.20% | 0.00% | Jun 2026 |
| Whitebox Advisors, LLC | 687K | 0.19% | -37.65% | Jun 2026 |
| GordonMD Global Investments LP | 573K | 0.16% | 0.00% | Jun 2026 |
| Tudor Investment Corp Et AL | 532K | 0.15% | +41.33% | Jun 2026 |
| UBS Group AG | 465K | 0.13% | +2.65% | Jun 2026 |
| The Goldman Sachs Group Inc | 420K | 0.12% | +43.47% | Jun 2026 |
| SONA ASSET MANAGEMENT (US) LLC | 404K | 0.11% | 0.00% | Jun 2026 |
Bausch + Lomb Corp company profile
- Company name
- Bausch + Lomb Corp
- Ticker
- BLCO.US
- ISIN
- CA0717051076
- Exchange
- USA Stocks
- Listed since
- May 6, 2022
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 13,000
- Fiscal year end
- December
- Address
- 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4
- Phone
- 905 695 7700
- Website
- bausch.com
About Bausch + Lomb Corp
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
Bausch + Lomb Corp management
10- Mr. Osama A. EldessoukyExecutive VP & CFO · born 1972
- Mr. A. Robert D. BaileyExecutive VP & Chief Legal Officer · born 1963
- Dr. Yehia Hashad M.D., Ph.D.Executive VP of Research & Development and Chief Medical officer · born 1968
- Mr. Andrew J. StewartPresident of Global Pharmaceuticals & International Consumer · born 1976
- Mr. Thomas J. AppioInterim CEO & Chairman of the Board · born 1962
- Mr. Alan Waterhouse CPFA, MBAExecutive VP and Chief Supply Chain & Operations Officer · born 1960
- Mr. Frederick J. MunschSenior VP, Controller & Chief Accounting Officer · born 1970
- Mr. George GadkowskiVP & Head of Investor Relations & Business Insights
- Mr. Jonathon L. KellermanChief Compliance Officer
- Mr. T.J. CrawfordChief Communications Officer